Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i Activities Highlights
10 -12 june 2017, St Petersburg, Russia
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
Read full report..
R3i editorial
16 October 2017

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Remnants and residual cardiovascular risk: triglycerides or cholesterol?Read more...

Non-high-density lipoprotein cholesterol (non-HDL-C) is recognized as a key therapeutic target, especially in subjects with a lipid profile characterized by elevated triglycerides and low HDL-C levels (atherogenic dyslipidaemia), which is prevalent in individuals with insulin resistant conditions such as type 2 diabetes mellitus. Non-HDL-C encompasses the total burden of atherogenic apolipoprotein B-containing lipoproteins, and therefore includes low-density lipoproteins (LDL).
 
But in the setting of well controlled LDL cholesterol (LDL-C) levels with intensive statin therapy, as evident in the REVEAL study, or with combination LDL- lowering regimens such as in IMPROVE-IT (ezetimibe) or FOURIER (evolocumab), can we perhaps refine this measure – or define more specific therapeutic approaches?
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
16 October 2017

REVEAL: modest benefit on major coronary events with anacetrapibRead more...

The results of the REVEAL trial indicate a modest benefit with anacetrapib against a background of well controlled LDL-C levels in secondary prevention patients. Treatment was well tolerated, albeit there was still a signal for elevated blood pressure, as seen with other CETP inhibitors (torcetrapib...
focus on...
16 October 2017

Atherogenic lipoproteins and residual cardiovascular risk: the role of triglyceride-rich lipoproteinsRead more...

Guidelines have recognized the importance of the total burden of atherogenic apoB-containing lipoproteins, including LDL, to cardiovascular risk.1 In the setting of well controlled LDL-C levels, as in the on-statin study group in JUPITER, apoB-containing lipoproteins other than LDL may be more relevant contributors to...
recent publication

Composite endpoints in clinical trials in type 2 diabetesRead more...

Composite endpoints are conventionally used in clinical outcomes studies to increase statistical power and precision. More recent outcomes studies in...
recent publication

Target non-HDL-C to reduce residual cardiovascular risk factors in diabetesRead more...

This study from Taiwan provides valuable insights into the relevance of different residual cardiovascular risk factors in a prospective cohort...
recent publication

Nonfasting triglycerides/high-density lipoprotein cholesterol ratio predicts cardiovascular events after PCIRead more...

There is a growing body of evidence supporting atherogenic dyslipidaemia, the combination of elevated fasting triglycerides and low plasma concentration...
recent publication

Atherogenic dyslipidaemia in rheumatoid arthritisRead more...

Emerging data suggest a link between triglyceride-rich lipoproteins, inflammation and atherogenesis. This study adds to this, suggesting that increased number...
recent publication

Pemafibrate (K-877) attenuates postprandial hypertriglyceridemia in miceRead more...

Pemafibrate is a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM?) with higher activity and selectivity for the PPAR? receptor...
recent publication

EURIKA: Need to do better in managing atherogenic dyslipidaemia in primary preventionRead more...

According to the latest report from the EURIKA study, one in five patients without a history of cardiovascular events, have...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.